SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mulherin D, FitzGerald O, Bresnihan B. Synovial tissue macrophage population and articular damage in rheumatoid arthritis. Arthritis Rheum 1996; 39: 11524.
  • 2
    Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000; 2: 189202.
  • 3
    Liu H, Pope RM. Phagocytes: mechanisms of inflammation and tissue destruction. Rheum Dis Clin North Am 2004; 30: 1939.
  • 4
    Richards PJ, Williams AS, Goodfellow RM, Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 1999; 38: 81825.
  • 5
    Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 19519.
  • 6
    Bondeson J. The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol 1997; 29: 12750.
  • 7
    Smith MD, Kraan MC, Slavotinek J, Au V, Weedon H, Parker A, et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatology (Oxford) 2001; 40: 36774.
  • 8
    Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNFα monoclonal cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine 1995; 7: 2519.
  • 9
    Feldmann M, Elliot MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283350.
  • 10
    Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, et al. Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 160916.
  • 11
    Turk MJ, Breur GJ, Widmer WR, Paulos CM, Xu LC, Grote LA, et al. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum 2002; 46: 194755.
  • 12
    Nagayoshi R, Nakamura M, Ijiri K, Yoshida H, Komiya S, Matsuyama T. Ly309887, antifolate via the folate receptor suppresses murine type collagen II-induced arthritis. Clin Exp Rheumatol 2003; 21: 71925.
  • 13
    Ross JF, Wang H, Behm FG, Mathew P, Wu M, Booth R, et al. Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999; 85: 34857.
  • 14
    Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW, Low PS. Expression and functional characterization of the β-isoform of the folate receptor on CD34+ cells. Blood 1999; 93: 39408.
  • 15
    Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor β-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 2002; 100: 594602.
  • 16
    Kreitman RJ. Chimeric fusion protein-Pseudomonas exotoxin-based. Curr Opin Investig Drugs 2001; 2: 128293.
  • 17
    Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003: 52: 33841.
  • 18
    Thepen T, van Vuuren AJ, Kiekens RC, Damen CA, Vooijs WC, van de Winkel JG. Resolution of cutaneous inflammation after local elimination of macrophages. Nat Biotechnol 2000; 18: 4851.
  • 19
    Bruhl H, Cihak J, Stangassinger M, Schlondorff D, Mack M. Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV. J Immunol 2001; 166: 24206.
  • 20
    Van Roon JA, van Vuuren AJ, Wijngaarden S, Jacobs KM, Bijlsma JW, Lafeber FP, et al. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcγ receptor I–directed immunotoxin. Arthritis Rheum 2003; 48: 122938.
  • 21
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 22
    Matsuyama T, Nakashima N, Matsuda T, Nakamura H, Uchida S, Abe T. Induction of multinucleated giant cells from rheumatoid arthritis (RA) synovial adherent cells by anti-DR antibody. Clin Exp Immunol 1994; 98: 25763.
  • 23
    Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990; 18: 5322.
  • 24
    Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 2000; 23: 4739.
  • 25
    Carroll SF, Collier R. Active site of Pseudomonas aeruginosa exotoxin A: glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem 1987; 262: 870711.
  • 26
    Graham FL, Prevec L. Manipulation on adenovirus vectors. In: MurrayEJ, editor. Gene transfer and expression protocols: methods in molecular biology. Vol. 7. Clifton (NJ): The Humana Press; 1991. p. 10928.
  • 27
    Mayne GC, Borowicz RA, Greeneklee KV, Finlay-Jones JJ, Williams KA, Hart PH. Centrifugation facilitates transduction of green fluorescent protein in human monocytes and macrophages by adenovirus at low multiplicity of infection. J Immunol Methods 2003; 278: 4556.
  • 28
    Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 2719.
  • 29
    Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995; 96: 16318.
  • 30
    Piedrahita JA, Oetama B, Bennett GD, van Waes J, Kamen BA, Richardson J, et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet 1999; 23: 22832.
  • 31
    Nakamura M, Nagayoshi R, Ijiri K, Nakashima-Matsushita N, Takeuchi T, Matsuyama T. Nitration and chlorination of folic acid by peroxynitrite and hypochlorous acid, and the selective binding of 10-nitro-folate to folate receptor β. Biochem Biophys Res Commun 2002; 297: 123844.
  • 32
    Cauli A, Yanni G, Panayi GS. Interleukin-1, interleukin-1 receptor antagonist and macrophage populations in rheumatoid arthritis synovial membrane. Br J Rheumatol 1997; 36: 93540.
  • 33
    Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004; 56: 106784.
  • 34
    Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004; 56: 112741.
  • 35
    Nagata S, Onda M, Numata Y, Santora K, Beers R, Kreitman RJ, et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res 2002; 8: 234555.
  • 36
    Onda M, Wang GC, Guo HF, Cheung NK, Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 2004; 64: 141924.
  • 37
    Kreitman RJ, Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin Cancer Biol 1995; 6: 297306.
  • 38
    Paulos CM, Turk MJ, Breur GJ, Loe PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004; 56: 120517.
  • 39
    Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002; 14: 54852.